Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

被引：11

作者：

Liu, Ning ^{[1
]}

Yan, Limei ^{[1
]}

Shan, Fengping ^{[2
]}

Wang, Xiaonai ^{[2
]}

Qu, Na ^{[3
]}

Handley, Mike K. ^{[4
]}

Ma, Mingxing ^{[5
]}

机构：

[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

[2] China Med Univ, Dept Immunol, Coll Basic Med Sci, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China

[3] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Gynecol, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China

[4] Cytocom Inc, 37 North Orange Ave,Suite 607, Orlando, FL 32801 USA

[5] China Med Univ, Shengjing Hosp, Dept Gen Surg, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 04期

关键词：

Low-dose naltrexone; Cervical cancer; Proliferation; Invasion; PI3K; AKT; mTOR; EPITHELIAL-MESENCHYMAL TRANSITION; METASTASIS; SNAIL2; LDN;

D O I：

10.1016/j.tranon.2021.101028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilities of colony formation, migration and invasion in cervical cancer cells. LDN could also inhibit cervical cancer progression in mice model. Moreover, LDN indirectly reduced the expressions of PI3K, pAKT and mTOR in vitro and in vivo. Therefore, LDN may be considered a potential treatment option for cervical cancer.

引用

页数：8

共 50 条

[21] TMAO promotes dementia progression by mediating the PI3K/Akt/ mTOR pathway
Hu, Xiaojuan
Zhang, Yamin
Gu, Cheng
Wu, Ruipeng
Yao, Yuping
Gao, Fulin
Luo, Lulu
Zhang, Yi
TISSUE & CELL, 2023, 81
[22] Correlation between the activation of PI3K/Akt/mTOR signaling pathway and the clinical prognosis in patients with cervical cancer
Liu, Yan
Li, Jianwen
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (12): : 16603 - 16610
[23] The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, Seiji
Kuroda, Hiromasa
Takahashi, Ryoko
Sasano, Tomoyuki
GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 173 - 179
[24] Gambogic acid affects ESCC progression through regulation of PI3K/AKT/mTOR signal pathway
Yu, Jiarui
Wang, Wei
Yao, Weinan
Yang, Zhao
Gao, Peng
Liu, Meiyue
Wang, Huan
Chen, Siyuan
Wang, Dan
Wang, Weixi
Sun, Guogui
JOURNAL OF CANCER, 2020, 11 (19): : 5568 - 5577
[25] Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance
Ediriweera, Meran Keshawa
Tennekoon, Kamani Hemamala
Samarakoon, Sameera Ranganath
SEMINARS IN CANCER BIOLOGY, 2019, 59 : 147 - 160
[26] Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells
Kang, Sokbom
Dong, Seung Myung
Kim, Boh-Ram
Park, Mi Sun
Trink, Barry
Byun, Hyun-Jung
Rho, Seung Bae
APOPTOSIS, 2012, 17 (09) : 989 - 997
[27] PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D
McLeod, HL
ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
[28] MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway
Fu, Ke
Zhang, Ling
Liu, Rui
Shi, Qi
Li, Xue
Wang, Min
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[29] Synaptopodin-2 plays an important role in the metastasis of breast cancer via PI3K/Akt/mTOR pathway
Xia, Erjie
Zhou, Xiaofen
Bhandari, Adheesh
Zhang, Xiaohua
Wang, Ouchen
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1575 - 1583
[30] Effects of curcumin on 5-fluorouracil resistance of colon cancer cells through the PI3K/AKT/mTOR pathway via MACC1
Ma, Xuefeng
Sun, Xu
Wang, Rongdi
Guo, Yutong
Xu, Meng
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2022, 56

← 1 2 3 4 5 →